Harpreet Arora, MD
Internal Medicine · Birmingham, ALNPI 1831696749
Payments from drug & device makers
Across 30 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$120
- Gilead$118
- Paratek Pharmaceuticals, Inc.$74
- Astellas Pharma US Inc$67
- AbbVie$57
- Melinta Therapeutics, LLC$49
- plus $128 from 4 others
What the payments were for
- Food & beverage$613100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $120 |
| Gilead | 5 | $118 |
| Paratek Pharmaceuticals, Inc. | 4 | $74 |
| Astellas Pharma US Inc | 4 | $67 |
| AbbVie | 3 | $57 |
| Melinta Therapeutics, LLC | 3 | $49 |
| Cumberland Pharmaceuticals, Inc. | 2 | $41 |
| La Jolla Pharmaceutical Company | 2 | $36 |
| Insmed, Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $22 |
How this compares
$613 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 82 | $37,630 |
| CeftriaxoneCeftriaxone Sodium | 56 | $17,332 |
| MicafunginMicafungin Sodium | 14 | $9,423 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 39 | $9,199 |
| ErtapenemErtapenem Sodium | 17 | $8,629 |
| Cefazolin Sodium | 33 | $4,855 |
| Cefepime Hcl | 17 | $4,594 |
| Vancomycin Hcl | 28 | $3,401 |
| Cefadroxil | 15 | $2,378 |
| Doxycycline Hyclate | 21 | $670 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $532 |
| Fluconazole | 13 | $380 |
| Levofloxacin | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.